End-Seq maps the location of 5’ and 3’ UTRs transcriptome-wide, providing detailed information to better understand RNA biology and develop more effective RNA therapeutics.
Contact usEnd-Seq identifies active UTRs, providing drug developers with key information on unique druggable targets.
Untranslated regions (UTRs) are important regulators of gene and mRNA therapeutic activity. Our End-Seq technology provides nucleotide-level mapping of the transcription start site (TSS) to identify 5’ UTRs and polyadenylation sites (PAS) to identify 3’ UTRs. The results of these assays can be used to identify unique druggable targets for small molecules or identify optimal UTRs for mRNA therapeutics.
Contact usOverview
Use:
Assess UTR usage
Typical species:
Human, mouse
Typical samples:
Total RNA
Map UTRs across the transcriptome
Ready to start your End-Seq project? Contact us today.
Contact usExtract RNA
RNA from either the cap (5’ End-Seq) or the tail (3’ End-Seq) is obtained
Sequence
Libraries are prepared and next-generation sequencing is performed
Analyze
Custom bioinformatics analyses map active UTR locations across the transcriptome
Discover the
UTR landscape
The following are some examples of the types of insights that End-Seq can provide. For our partners, we perform additional analyses to provide actionable insights for therapeutic success.
Reveal disease-specific regions
Different disease states can lead to the expression of different isoforms with specific UTR usage. End-Seq reveals which UTRs are active in a given disease state, providing small molecule developers with lists of druggable regions selectively active in the disease and cell type of interest.
A 5’ UTR is more active in cancerous samples and not in healthy samples, making it a potential target for selective regulation in cancer.
Discover optimal UTRs for mRNA therapeutics
To be effective, many mRNA therapeutics require UTRs that are active in the target cell type, have low endogenous regulation, and high stability. With End-Seq, we identify active UTRs with the cellular machinery in place to drive protein production. When paired with our other technologies, we can further refine UTR selection to minimize unwanted miRNA regulation while maximizing stability and translation.
Scatter plot of 5’ UTRs active in a cell line, each dot is a UTR determined by End-Seq. The x-axis is the relative translation of the associated gene per eRibo Pro and the y-axis is the relative stablity per eSHAPE.